Dementia and neurodegenerative conditions are a tremendous burden on our healthcare system and economy.
Souvien Therapeutics, Ltd. is a biotechnology company focused on developing novel therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.
Souvien is founded on the pioneering research of Dr. Li-Huei Tsai, PhD, the Director of The Picower Institute for Learning and Memory at MIT, and Associate Professor Dr. Stephen Haggarty, PhD, the director of the Chemical Neurobiology Laboratory at Harvard Medical School/Massachusetts General Hospital.
The development plan is based on a substantial body of data implicating a critical epigenetic regulator of cellular aging in neurodegeneration. The goal is to use that knowledge, and the greatly evolving understanding of aging, to bring new drugs into human trials.
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.